Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders

Current Opinion in Rheumatology

Volumn 21, Issue 5, 2009, Pages 552-557

  Woo, Patricia ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autoinflammatory syndromes; Juvenile dermatomyositis; Juvenile idiopathic arthritis; Macrophage activation; Scleroderma; Systemic lupus erythematosis

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; CHILD; CHILDHOOD DISEASE; CHRONIC INFLAMMATION; DERMATOMYOSITIS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS; WEGENER GRANULOMATOSIS;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; AUTOIMMUNE DISEASES; CHILD; DERMATOMYOSITIS; FAMILIAL MEDITERRANEAN FEVER; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SCLERODERMA, LOCALIZED; SYNDROME; WEGENER GRANULOMATOSIS;

EID: 69549096591     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832f142e     Document Type: Review

References (38)

1. Simon D. Management of growth retardation in juvenile idiopathic arthritis. Horm Res 2007; 68 (Suppl 5):122-125.
2. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology (Oxford) 2002; 41:1440-1443. (Pubitemid 36004324)
3. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: education and employment. Rheumatology (Oxford) 2002; 41:1436-1439. (Pubitemid 36004323)
4. PackhamJC,Hall MA. Long-termfollow-up of 246adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002; 41:1428-1435. (Pubitemid 36004322)
5. Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology (Oxford) 2002; 41:1444-1449. (Pubitemid 36004325)
6. McDonagh JE. Young people first, juvenile idiopathic arthritis second: transitional care in rheumatology. Arthritis Rheum 2008; 59:1162-1170. This is an excellent review of the rationale for adolescent-specific care and the evidence so far.
7. Gurcay E, Eksioglu E, Yuzer S, et al. Articular damage in adults with juvenile idiopathic arthritis. Rheumatol Int 2009; 29:635-640.
8. Barr T, Carmichael NM, Sandor GK. Juvenile idiopathic arthritis: a chronic pediatric musculoskeletal condition with significant orofacial manifestations. J Can Dent Assoc 2008; 74:813-821. This study highlights the consequences of chronic inflammation of the temporomandibular joints, which are usually missed due to lack of reporting of symptoms until significant changes occur.
9. Wulffraat NM, van Rooijen EM, Tewarie R, et al. Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis. Autoimmunity 2008; 41:632-638.
10. Rabusin M, Andolina M, Maximova N. Haematopoietic SCT in autoimmune diseases in children: rationale and new perspectives. Bone Marrow Transplant 2008; 41 (Suppl 2):S96-S99. This is an excellent summary of where we are currently with this modality of treatment. (Pubitemid 351864717)
11. Abinun M, Flood TJ, Cant AJ, et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007). Mol Immunol 2009. [Epub ahead of print]
12. Saba NS, Kosseifi SG, Charaf EA, Hammad AN. Adalimumab-induced acute myelogenic leukemia. South Med J 2008; 101:1261-1262.
13. Emery P, Genovese MC, van Vollenhoven R, et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009. [Epub ahead of print] This is the latest in publications from this unit of clinical trials showing superior radiographic as well as clinical results with combination of anti-TNF and methotrexate versus monotherapy.
14. Bartoli M, Taro M, Magni-Manzoni S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008; 67:370-374. (Pubitemid 351281273)
15. van Rossum MA, van Soesbergen RM, Boers M, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007; 66:1518-1524. (Pubitemid 350032663)
16. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31:390-392. (Pubitemid 38160763)
17. Unsal E, Makay B. Intraarticular triamcinolone in juvenile idiopathic arthritis. Indian Pediatr 2008; 45:995-997.
18. Beukelman T, Guevara JP, Albert DA. Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008; 59:1580-1588. This study is a good synthesis of when to use intra-articular steroid.
19. Edelsten C. Reconsidering treatment options in childhood uveitis. Br J Ophthalmol 2007; 91:133-134. (Pubitemid 46202853)
20. Hayward K, Wallace CA. Recent developments in antirheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009; 11:216. This is a comprehensive up-to-date review of all the therapeutic options in JIA.
21. Ho TY, Chung YM, Lee AF, Tsai CY. Severe vaso-occlusive retinopathy as the primary manifestation in a patient with systemic lupus erythematosus. J Chin Med Assoc 2008; 71:377-380.
22. Hunt BJ. Pediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2008; 34:274-281.
23. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multiethnic cohort. Ann Rheum Dis 2009; 68:238-241.
24. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61:29-36.
25. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 2008; 47:1498-1502.
26. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52:3168-3174. (Pubitemid 41447099)
27. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 2009; 123:e159-e163. This study provides evidence base so far for the use of B-cell depletion therapy in SLE.
28. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008; 58:3585-3592.
29. Sultan SM, Ng KP, Edwards JC, et al. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008; 26:887-893.
30. Weibel L, Howell KJ, Visentin MT, et al. Laser Doppler flowmetry for assessing localized scleroderma in children. Arthritis Rheum 2007; 56: 3489-3495. (Pubitemid 47585445)
31. Weibel L, Sampaio MC, Visentin MT, et al. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol 2006; 155:1013-1020. (Pubitemid 44564513)
32. Faurschou M, Mellemkjaer L, Sorensen IJ, et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009; 60:1187-1192. This study is one of the few studies that address the issue of the consequences of chronic vasculitis.
33. Chan M, Luqmani R. Pharmacotherapy of vasculitis. Expert Opin Pharmacother 2009; 10:1273-1289.
34. Jayne D. Review article: Progress of treatment in ANCA-associated vasculitis. Nephrology (Carlton) 2009; 14:42-48. An excellent review.
35. Flossmann O, Jayne DR. Maintaining remission in a patient with vasculitis. Nat Clin Pract Rheumatol 2008; 4:499-504. This is a comprehensive review of the current practice that is still far from ideal. Antibiotic treatment is an important component in maintenance of remission of this disorder.
36. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009; 27:621-668. An excellent review of this group of disorders.
37. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355:581-592. (Pubitemid 44200651)
38. Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin- 1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58:2432-2442.